one of the names we are looking at is novartis. i'll get to that shortly.e have autos up and construction up 1.3. the banks are also up 1% now as well. on the down side, basic resources dragged down by the weaker data we had out of china yesterday with industrial profits in china plunging 23% in the first two months of the year. that is having a knock-on effect on basic resources in europe. in terms of individual stocks, let's point out novatis up 5%. bearing back half of the losses we saw on friday. we also have some of the italian banks trading heavy under water today. we have banc down 4% as well. we are not out of the woods for the european banking system. there is focus on the italian banks as well. >>> let's tell you what is going on with novartis. it is 6% higher today. the company says the breast cancer drug has proven to cut risk in female patients. the late stage trial for the drug showed positive results alongside endocrine therapy. that is promising in the field of cancer. the breast cancer drug producing good results there. s have -- having a p

novartis shares are jumping right now, about xd7.5%, 8% aft its breast cancer drug showed initial trialrates this year? the majority of you say, no, they will not. up next, trading techs. power e*trade's award-winning trading app makes trading easier. with its customizable options chain, easy-to-use tools, and paper trading to help sharpen your skills, you can stay on top of the market from wherever you are. power e*trade's easy-to-use tools make complex trading less complicated. custom scans help you find new trading opportunities. while an earnings tool helps you plan your trades and stay on top of the market. the one wheráhvárp+e banks pulling. pulling. >> you can hear the bell. out with a gain. s&p ended oute1 positive. nasdaq giving it up right at the end. that does it for us. qgut >>> well, got tig scorecard on wall street, but winners stay late. welcome to closing bell overtime. we're going to talk tow3 robert shiller about the commercial anp residential real estate market ár(q day. ár(q >>> plus we'll have an analyst about the fallout for crypto-related stocks. look at that char

called it a big step and with great cooperation, after two big companies in the world, i did this for novartis company, this is the third time in iran. this happened to a cancer patient who could not be cured in any way the case of death of the child has found the order related to normal life now, and it is completely only the state of complete relief. imam mahdi hospital's response in terms of training for relapses, 200 and 300 specialists and 675 general doctors pass through the hospital and use nurses. dear, between the dear medical community and rehabilitation to a specialized site, the amount of economic calculations, the center of which is in the patients we heal, the patient in the elevator, at least 10 thousand people will be saved from death in imam khomeini hospital, like a simple person, a simple worker, an efficient economy, 250 thousand it is worth the dollar let's do 10,000. it was something like 3 billion dollars a year. imam khomeini hospital is the only health economy that can help. therefore, it should be based on spiritual values, because all these flowers will save the whol

you must be excited. >> i sold lilly and novartis, as good as these drugs, are as gigantic as i thinkwas sort of like the "star wars" box office, buy the rumor, sell the news and once it started selling, it's fantastic life-changing products, but i'm out right now. >> yeah. >> that $20 billion estimate is going to take years, and when you think about it off a 30 billion barracks i mean, that's serious growth over the next several years and this stock has sold off 375, trade 2:0010 today. i think -- guy said it last night, 25 times, this is the most expensive large pharma stock that you have and tim was talking about pfizer on the flip side t.trades at well below many of its peers you would probably go with lilly here. >> and lilly actually has underperformed the market and its pence, and when you talk about the new drug, the diabetes drug, they project that to be 27% of revenue where the two insulin drugs are 18% of revenue so they are going in the right direction, but the market really hasn't rewarded them in the past they have definitely underperformed i wonder if that underperforma

novartis has a swiss company, but the multinational company has a price of about 430,000 dollars . it is very difficult, but the language is different. we are the manufacturer beshim's product becomes cheaper in the country by local scientists and is being developed in knowledge-based companies to treat cancers. it is really a very important leap in iran's medical technology. a large number of young people believe that god was very good. it is not an ideal for parents. i said to one of my hematologist colleagues, "you don't have anything between ilam and the support , what should i look for?" he said, "let's see if you can find something later . it was a very good feeling . iran is one of the three countries that have the technology of exorcism in the world is the parliament to review the details of the plan he started amending the construction worker insurance law. according to this plan, 500,000 construction workers who are in line for insurance will be insured. 4% of the minimum monthly wage for urban infrastructures is 1% for rural areas. in big cities , commercial uses should

healthcare and novartis is a big part of this mix.t more details on that story around a breast cancer drug in optimism around the progress on that front every single sector this monday morning in the green. basic resources just range bound despite brecht is it coming and higher for the session. francine: deutsche bank shares are up in early trade after the german lender was at the epicenter of another selloff in shares heading into the weekend. let's talk about german banks with our reporter steven arons in frankfurt. it was shocking to see deutsche bank stock hit so hard on friday. what were the underlying reasons? >> it seems like it was market nervousness as we remember. just the weekend before, credit suisse had to be rescued because people were plenty -- pulling money out of it and that created a lot of tension across the banking industry in europe and add to that the problems in regional inks in the u.s.. there was a bit of a trigger event on friday that was enough to set off really nervousness about deutsche bank and that cap g

novartis up 7.7% today.news on one of its oncology drugs designed to target breast cancer coming through today. the market responding positively to that news. all good news. want to come back to this issue of strikes. ids, used to be known as the royal mail, down by 4.3% today. downgraded. this goes to the heart of the story. the narrative is a concern strikes are going to eat into this company's ability to cut costs. manage the p&l, manage the margin story. i think that is going to be evident elsewhere around europe when we talk at the top of the show about what is happening in paris, strikes in germany today, big strikes in france tomorrow. let's talk about what we are going to see tomorrow, tuesday. we've got andrew bailey, the governor of the bank of england testifying in the u.k. on the way the u.k. handled its part of the svb crisis. we get data, the italian consumer confidence data, manufacturing confidence data. forward-looking indicators, the softer confidence indicators may capture the impact of wh

. >>> novartis announced a $11 billion share buyback.t will buy the stock over the next three years and that proves there are other stories happening this morning it will buy a company worth 2.9billion it will gain access to the treatment for type one diabetes. >>> u.s. firm silvergate signed a deal to buy qualtrics and take it private for $12.5 billion it is set to get $7.76 billion from the deal after silvergate and canadian investment board purchased it at $18.15 per share. >>> porsche came in below e expectation for 2023 revenue it is targeting $40 billion euro for this year and setting a target of 20%. >>> now coming up on the show, we will have the latest as hsbc offers to buy uk arm of silicon valley bank in a deal for 1 pound. stay with us we are back right after this ah, these bills are crazy. she has no idea she's sitting on a goldmine. well she doesn't know that if she owns a life insurance policy of $100,000 or more she can sell all or part of it to coventry for cash. even a term policy. even a term policy? even a term policy

i got on the public pressure, sundance, which would later become novartis from which syngenta would emerge, had to relocate his production to the united states. the company been sold at present in europe for another 16 years. ah. ah, just like actress zane the use of power quite is also forbidden in the youth, but not its production power quite as manufactured in england. in 2018, it made up one 3rd of the volume of substances. the e u has banned for years. but still cynically exports to the rest of the world. a backwards sit on their receipt era. kwan is an extremely toxic herbicide that was developed in the 1960 dia did. erica. so it's been on the market for almost 60 years. you see this of mash, this herbicide is so toxic that swallowing just one teaspoon is fatal. started a korea cafe, a cit, every year. this herbicide poisoned thousands of farmers and developing countries which are getting on people who use it without proper protective gear and inhale it or their skin comes into contact with that. none of you. so i spoke of our lepeu ah, but are quite as still approved for use in some

novartis having a really solid session, up about 8%.with, would make it on pace for its largest percentage gain since march of 020 the after reporting positive trial results for its breast cancer drug. the trial day a show a significant reduction in the recurrence of early stage breast cancer. jeffreys says the drug could represent -- usually it's a $1 billion, this is a $6 billion sales opportunity for the pharma company. we shall see. in the meantime, silverdate cammal -- silvergate capital gaining at this hour after it was reported it voluntarily prepaid the remaining principal on its $205 million loan from the crypto bank. so silvergate shares jumping 16.5%. we should mention, of course, it's currently in the process of lick by candidating its banking business operations. the death blow came from mass withdrawals triggered by the november collapse of and fraud allegations against crypto brokerage ftx. so while we cough microstrategy down about a # %5% right now, it has recovered its post-ftx bankruptcy losses and is up about 21% ove

. >> reporter: and so novartis is saying to prescribe only to people who are living with type i i diabeteshe new progress. >> the option of getting it without paying a lot of money are not looking great for me. >> reporter: stephanie gosk, nbc news. >>> well, in today's mental health check, getting a divorce can be a devastating experience emotionally and financially, and impact your physical health as well. >> and it is important to find the right words to say, but it is not always easy. joining us is a licensed clinologist, and how can you best support a loved ones going through a divorce. >> it is easy way to support a loved one. one is to be a good listener, and to allow someone to be thinking and feeling without interrupting and talking about your own experience, and another important tip is to learn how to not take sides, and it can be easy to take your loved one side when they are going through it, but sometimes they have mixed emotions about their partner, and not taking sides is a valuable way to be an open space to be themselves, and offer practical support like kid sitting or pe

novartis' sandos generic unit got back to us and said it's investing to support european manufacturingis is an all-too-familiar situation at this point, particularly for these old, cheap, generic drugs. we'll take a look deeper into that part of the story tomorrow in the second part of our series. becky? >> meg, is this more than the sort of supply chain issues that we've seen in other industries, especially after the pandemic. this was something that goes al deeper? >> it absolutely does. the pandemic exacerbated this, but it's been a problem that's been going on for decades, particularly for these old, inexpensive medicines. and so what we've seen with amoxicillin really is tied to that crazy flu, cold, rsv, all of these different bugs season, even though you wouldn't take antibiotics for rsv unless you have a secondary bacterial infection, so we heard about that through the winter, but we don't have reserves in our supply chains to make up for shortfalls when demand goes higher than expected. and certainly when there are interruptions like something like a pandemic or even less than